Biofortuna Ltd, a diagnostics company based in Wirral UK, announces significant investment into its IVD Contract Manufacturing Division in order to support continued growth.
Biofortuna’s new climate control system will allow for accurate control of environmental factors down to 5% relative humidity, resulting in unrivalled stability of lyophilised reagents. Packing in a low humidity environment ensures products are stored under optimal conditions for long-term, ambient temperature stability. 5% relative humidity also provides ideal conditions in which to pack lyophilised products and ensure there is no degradation of product during the packing procedures.
Biofortuna uses proprietary freeze-drying expertise and cryo-preservatives to stabilise complete PCR and immunoassay reactions into instantly soluble freeze-dried pellets. These freeze-dried kits are stable at ambient temperatures and only require the addition of patient sample prior to detection and analysis.
In addition to lyophilisation Biofortuna also offers contract R&D, manufacturing, dispensing and kitting of both molecular and immunoassay diagnostic products.
Dr Simon Douglas, Biofortuna CEO commented “This is a major step in the expansion of Biofortuna and is essential for our continued growth. This additional investment into infrastructure will allow us to improve our services and deliver high quality solutions to our customers.”
Biofortuna are one of a limited number of companies globally who offer freeze drying manufacturing services that are both CE and FDA registered and will continue focusing on producing high quality kits for the diagnostic and life science markets.
About Biofortuna Ltd
Biofortuna Ltd is a leading diagnostics company offering both custom manufacturing services and molecular diagnostic products. Biofortuna provides a complete solution for diagnostics companies looking to outsource elements of development and manufacture. Biofortuna’s lyophilisation technology provides easy-to-use diagnostics whilst increasing laboratory productivity and improving quality in clinical testing and patient care.
Biofortuna Media Contacts
Dr Simon Douglas
Chief Executive Officer